EP 1197550 A2 20020417 - Methods and compositions for diagnosing and treating disorders involving angiogenesis
Title (en)
Methods and compositions for diagnosing and treating disorders involving angiogenesis
Title (de)
Methoden und Zusammensetzungen zur Diagnose unde Behandlung von Krankheiten an denen Angiogenese beteiligt ist
Title (fr)
Méthodes et compositions pour diagnostiquer et traiter des troubles associés à l'angiogenèse
Publication
Application
Priority
US 22800000 P 20000825
Abstract (en)
The present invention relates to polynucleotides associated with angiogenesis-related disorders. The present invention also relates to canine angiostatin genes, novel genes associated with angiogenesis-related disorders, such as cancer. The invention encompasses angiostatin nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, angiostatin gene products and antibodies directed against such gene products, cloning vectors containing mammalian angiostatin gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of angiostatin genes and gene products and to using such compounds as therapeutic agents in the treatment of angiogenesis-related disorders, e.g., cancer. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of angiogenesis-related disorders, e.g., cancer, and to methods and compositions for the treatment these disorders.
IPC 1-7
C12N 9/68; C12N 15/62; C07K 16/40; C12Q 1/68; G01N 33/68; A01K 67/027
IPC 8 full level
A01K 67/027 (2006.01); A61K 31/7084 (2006.01); A61K 31/7088 (2006.01); A61K 39/395 (2006.01); A61K 45/00 (2006.01); A61K 48/00 (2006.01); A61P 3/10 (2006.01); A61P 7/00 (2006.01); A61P 9/00 (2006.01); A61P 15/00 (2006.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 25/00 (2006.01); A61P 27/02 (2006.01); A61P 27/06 (2006.01); A61P 27/16 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); C07K 19/00 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 9/68 (2006.01); C12N 15/09 (2006.01); C12Q 1/02 (2006.01); G01N 33/15 (2006.01); G01N 33/50 (2006.01)
CPC (source: EP US)
A61P 3/10 (2017.12 - EP); A61P 7/00 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 27/06 (2017.12 - EP); A61P 27/16 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); C12N 9/6435 (2013.01 - EP US); C12Y 304/21007 (2013.01 - EP US); A01K 2217/05 (2013.01 - EP US); C07K 2319/00 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
EP 1197550 A2 20020417; EP 1197550 A3 20021120; JP 2002355056 A 20021210; US 2003059417 A1 20030327
DOCDB simple family (application)
EP 01307230 A 20010824; JP 2001256030 A 20010827; US 15736902 A 20020529